[CLRB] Cellectar Biosciences, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 1.33 Change: 0.12 (9.92%)
Ext. hours: Change: 0 (0%)

chart CLRB

Refresh chart

Strongest Trends Summary For CLRB

CLRB is in the long-term down -87% below S&P in 3 years and down -100% below S&P in 20 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Cellectar Biosciences, Inc., a development stage biopharmaceutical company, develops compounds for the treatment and imaging of cancer. Its proprietary product candidates include I-124-CLR1404, a small-molecule, broad-spectrum, and cancer-targeting positron emission tomography (PET) imaging agent that is in Phase II clinical trial for glioblastoma, as well as in Phase I/II clinical trials for approximately 11 solid tumor indications; and CLR1502, a preclinical, cancer-targeted, and non-radioactive optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging. The company also develops I-131-CLR1404, a small-molecule, broad-spectrum, and cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells, as well as is in Phase Ib dose-escalation trial for patients with advanced solid tumors; and CLR1404, a cancer-targeted chemotherapy. The company was formerly known as Novelos Therapeutics, Inc. and cha

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-67.91% ROE-161.51% ROI
Current Ratio1.23 Quick Ratio Long Term Debt/Equity0.21 Debt Ratio1.29
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities Cash From Investing Activities-30 K Cash From Operating Activities-2.37 M Gross Profit
Net Profit-2.3 M Operating Profit-2.59 M Total Assets10.91 M Total Current Assets7.26 M
Total Current Liabilities5.9 M Total Debt460 K Total Liabilities6.32 M Total Revenue
Technical Data
High 52 week3.12 Low 52 week1.29 Last close1.49 Last change-6.88%
RSI4.41 Average true range0.15 Beta0.38 Volume446.49 K
Simple moving average 20 days-24.35% Simple moving average 50 days-29.14% Simple moving average 200 days-30.23%
Performance Data
Performance Week-17.22% Performance Month-39.18% Performance Quart-30.7% Performance Half-37.13%
Performance Year-42.91% Performance Year-to-date-3.87% Volatility daily2.47% Volatility weekly5.52%
Volatility monthly11.32% Volatility yearly39.22% Relative Volume319.58% Average Volume95.2 K
New High New Low

News

2020-06-03 09:00:10 | Cellectar Biosciences Announces Pricing of $20 Million Underwritten Public Offering

2020-06-01 08:00:10 | Cellectar Granted SME Status by the European Medicines Agency

2020-05-28 10:10:17 | Here’s How Hedge Funds Traded Cellectar Biosciences, Inc. CLRB During The Crash

2020-05-27 10:56:02 | Company News for May 27, 2020

2020-05-26 07:45:10 | Cellectar Receives FDA Fast Track Designation for CLR 131 in Lymphoplasmacytic Lymphoma/Waldenstrom’s Macroglobulinemia

2020-05-14 08:00:10 | Cellectar Granted Composition of Matter and Use Patent in Europe for CLR 131

2020-05-07 08:15:10 | Cellectar Reports First Quarter 2020 Financial Results and Provides a Corporate Update

2020-04-16 07:04:47 | Here's Why We're A Bit Worried About Cellectar Biosciences's NASDAQ:CLRB Cash Burn Situation

2020-03-09 08:00:10 | Cellectar Reports Financial Results for Year Ended December 31, 2019 and Provides a Corporate Update

2020-02-19 08:00:10 | Cellectar Biosciences Announces CLR 131 Achieves Primary Efficacy Endpoints from Its Phase 2 CLOVER-1 Study in Relapsed/Refractory B-cell Lymphomas and Completion of the Phase 1 Relapsed/Refractory Multiple Myeloma Dose Escalation Study

2020-01-17 06:41:26 | Should You Be Concerned About Cellectar Biosciences, Inc.'s NASDAQ:CLRB Historical Volatility?

2020-01-09 08:00:10 | Cellectar Biosciences to Host a CLR 131 Clinical Data Call with Its Phase 2 Lead Investigator on February 19, 2020

2020-01-07 08:00:10 | Cellectar Appoints Dr. Igor Grachev as Chief Medical Officer

2020-01-06 08:00:10 | Cellectar Receives Orphan Drug Designation for CLR 131 in Lymphoplasmacytic Lymphoma LPL

2019-12-19 08:00:10 | Cellectar Biosciences to Present at Biotech Showcase 2020

2019-12-16 08:00:10 | Cellectar Announces Data From 20 Patients Receiving a Single 25mCi/M2 Bolus Dose of CLR 131 in the Phase 2 CLOVER-1 Study

2019-12-13 08:31:10 | Cellectar Presents Poster at the American Association for Cancer Research AACR San Antonio Breast Cancer Symposium

2019-12-09 08:30:10 | Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma Presented at the 61st Annual American Society of Hematology Conference

2019-12-02 08:30:10 | Cellectar Announces Oral Presentation at the 61st Annual American Society of Hematology Conference

2019-11-12 08:00:00 | Cellectar Reports Third Quarter 2019 Financial Results and Provides a Corporate Update

2019-10-30 08:00:05 | Cellectar Presents a New Phospholipid Drug Conjugate PDC at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

2019-10-19 09:44:40 | Is Cellectar Biosciences NASDAQ:CLRB In A Good Position To Invest In Growth?

2019-10-17 08:00:00 | Cellectar Announces Poster at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston

2019-10-15 08:00:00 | Cellectar Presents Poster at the Cancer Research UK-AACR Joint Conference on Engineering and Physical Sciences in Oncology

2019-10-08 08:00:00 | Cellectar Announces Presentation at the Cancer Research UK-AACR Joint Conference on Engineering and Physical Sciences in Oncology

2019-09-30 08:30:00 | Cellectar Presents Data from DLBCL Cohort of its Phase 2 CLOVER-1 Study at the European Society for Medical Oncology ESMO Congress

2019-09-24 08:00:00 | Cellectar Receives Orphan Drug Designation from the European Commission for CLR 131 in Multiple Myeloma

2019-09-19 08:30:00 | Cellectar Biosciences to Present at the Ladenburg Thalmann 2019 Healthcare Conference

2019-09-16 08:30:00 | Cellectar Presents Data from Cohort 6 of its CLR 131 Phase 1 Study in Patients with Relapsed or Refractory Multiple Myeloma

2019-09-10 08:00:00 | Cellectar Announces Oral Presentation at the European Society for Medical Oncology ESMO Congress 2019

2019-09-04 08:00:00 | Cellectar Announces Late-Breaker Poster Presentation at the 17th International Myeloma Workshop

2019-08-20 12:37:22 | Can We See Significant Institutional Ownership On The Cellectar Biosciences, Inc. NASDAQ:CLRB Share Register?

2019-08-15 08:30:00 | Cellectar Appoints Dov Elefant as Chief Financial Officer

2019-08-14 08:30:00 | CLR 131 Advances to Second Malignant Brain Tumor Cohort of Ongoing Pediatric Phase 1 Study

2019-08-12 08:00:00 | Cellectar Reports Second Quarter 2019 Financial Results and Provides a Corporate Update

2019-07-09 08:30:00 | Cellectar Receives FDA Fast Track Designation for CLR 131 in Diffuse Large B-Cell Lymphoma

2019-05-21 08:30:00 | Cellectar Expands Third Cohort of its Phase 2 CLOVER-1 Study of CLR 131

2019-05-20 16:10:17 | Cellectar Biosciences Announces Closing of $10.0 Million Financing

2019-05-18 07:15:48 | 5 Biotech Stocks to Watch in the Second Half of 2019

2019-05-16 08:52:36 | Cellectar Biosciences Announces $10.0 Million Financing

2019-05-15 08:30:00 | CLR 131 Achieves 50% Overall Response Rate in Cohort 6 of Ongoing Phase 1 Study in Relapsed or Refractory Multiple Myeloma

2019-05-13 08:00:00 | Cellectar Receives FDA Fast Track Designation for CLR 131 in Relapsed or Refractory Multiple Myeloma

2019-05-06 08:00:00 | Cellectar Reports First Quarter 2019 Financial Results and Provides a Corporate Update

2019-05-02 14:18:14 | 5 Biotech Stocks With Near-Term Catalysts Ahead

2019-04-29 10:20:00 | Cellectar Biosciences, Inc. NASDAQ:CLRB: Are Analysts Right About The Drop In Earnings?

2019-04-10 13:40:13 | 5 Oncology Companies That Are Set to Run

2019-03-19 08:30:00 | FDA Grants Exemption to Import Alert for Cellectar’s CLR 131 in Pediatric and Adolescent Patients

2019-02-26 08:30:00 | Cellectar Reports Financial Results for Year Ended December 31, 2018 and Provides a Corporate Update

2019-02-25 08:30:00 | Cellectar Reports Positive Top-line Response Rate of 30% from R/R Multiple Myeloma Cohort in Ongoing Phase 2 Study of CLR 131

2019-02-05 08:30:00 | Cellectar Biosciences to Present at the Annual BIO CEO & Investor Conference